drugset
drugset / Trial / NCT05344248

Safety, Tolerance, Efficacy and Pharmacokinetics of JS005 Multiple Dosing

NCT05344248 ↗

Phase 1/2 Completed 183 enrolled Shanghai Junshi Bioscience Co., Ltd.
RandomizedSequentialQuadruple-blindTreatment

Summary

JS005-002 is a randomized, double-blinded, placebo-controlled phase Ib/II clinical study to evaluate the safety, tolerability, efficacy and pharmacokinetic profiles of multiple doses of JS005 (recombinant humanized anti-IL-17A monoclonal antibody) Injection in patients with moderate to severe psoriasis.

Timeline

Start
2021-01-20
Primary completion
2022-10-28
Completion
2022-11-01

Drugs

EvaluationDrugModalityDoseRoute
Subject ROCONKIBART Monoclonal antibody 60 mg Subcutaneous
Subject ROCONKIBART Monoclonal antibody 150 mg Subcutaneous
Subject ROCONKIBART Monoclonal antibody 300 mg Subcutaneous
Subject ROCONKIBART Monoclonal antibody 600 mg Subcutaneous

Indications

psoriasis